Cytokinetics Inc (CYTK)
Debt-to-equity ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | -135,372 | -13,911 | 108,550 | -396,160 | -386,323 | -438,801 | -333,115 | -229,020 | -107,900 | -15,977 | 111,414 | 116,261 | 243,863 | 249,020 | 16,489 | 67,846 | 113,383 | 149,605 | -78,080 | -45,711 |
| Debt-to-equity ratio | — | — | 0.00 | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $-135,372K
= —
The debt-to-equity ratio of Cytokinetics Inc has shown a consistent trend of 0.00 from September 2020 to June 2022. This indicates that the company had no debt during this period, and its financing was primarily through equity. The absence of debt obligations can be seen as a positive sign, as it signifies lower financial risk and potential for financial stability.
From June 2024 onwards, the debt-to-equity ratio data is not available (marked as "\u2014"), indicating a lack of clarity regarding the company's financial structure in those periods. It is important for stakeholders to monitor and analyze additional financial information to gain a comprehensive understanding of Cytokinetics Inc's leverage and capital structure.
Peer comparison
Dec 31, 2024